Second Restructuring to Concentrate Capital on Clinical Assets

Ensoma, Inc. is temporarily suspending all preclinical programs and further reducing related personnel to focus resources on EN-374, a treatment for X-linked chronic granulomatous disease (X-CGD). This follows a previous restructuring in November 2025, which reduced the workforce by 50% (37 employees). This decision will also slow down the company's internal progress on multi-lineage CAR-T cell therapies for solid tumors and research on sickle cell disease. The company believes that prioritizing proof-of-concept for its sole clinical asset is crucial for securing future funding and enhancing its negotiating position for business development deals, rather than expanding its platform.

First In-Vivo HSC Therapy Targeting CYBB Function Restoration

EN-374, currently in clinical trials under a development code rather than a brand name or international nonproprietary name (INN), is a single-dose gene therapy that directly delivers a normal CYBB transgene to hematopoietic stem cells (HSCs) via virus-like particles (VLPs). The goal is to restore CYBB protein and NADPH oxidase activity, which is essential for immune defense, in the generated neutrophils. This differs from ex vivo approaches that require cell harvesting and manipulation. However, the treatment process involves HSC mobilization, short-term immunosuppressive therapy, and three cycles of in vivo selective amplification, so actual safety and efficacy must be demonstrated through clinical data.

Phase 1/2 Trial with 15 Patients is a Key Factor in Corporate Valuation

NCT06876363, which is recruiting patients in the United States and the United Kingdom, is an open-label Phase 1/2 trial that will progress from adult dose escalation to pediatric dose expansion. The target enrollment is 15 patients, and the primary completion date is scheduled for December 2027. The first patient was dosed in December 2025, and preliminary data from the first participant, released in May 2026, showed that all treatment-related adverse events were low-grade, with no serious adverse events or dose-limiting toxicities. Efficacy will be assessed based on the proportion of DHR-positive neutrophils and the achievement of a 10-50% threshold, meaning that sustained generation of functional neutrophils, rather than initial tolerability in a single patient, will determine the company's ability to raise funds.

Regulatory Support, but High Competitive Standards

The FDA granted EN-374 orphan drug and rare pediatric disease designations on February 13, 2025, and the UK MHRA approved the clinical trial application in December 2025. However, approvals or advisory committee reviews by the FDA, EMA, and PMDA are not yet on the agenda. The current standard of care is interferon gamma-1b (Actimmune), prophylactic antibiotics and antifungals, and allogeneic hematopoietic stem cell transplantation. Actimmune was approved by the FDA on December 20, 1990. A competing product in development is PM359, a prime editing therapy for NCF1-mutation CGD, which is in Phase 1/2 clinical trials by Prime Medicine (PRME). The global CGD treatment market was valued at $1.27 billion in 2024 and is projected to reach $1.77 billion in 2032. Therefore, EN-374 must demonstrate not only accessibility but also durability and infection reduction. Takeda Pharmaceutical Company Limited (TAK) has a contract that includes up to $100 million in upfront and preclinical research funding, a $10 million equity investment, and potential payments of up to $1.25 billion, plus low double-digit royalties based on net sales. However, the reduction in preclinical programs may affect the pace of development for up to five rare disease programs.